The importance of the results analyzed in this work led us to design an in vivo study in PC-3 tumours on the combined effect of the GHRH antagonist MIA-690 and the reversible EGFR inhibitor Gefitinib, a chemotherapeutic agent approved for clinical use in lung cancer. This evidence concerns the gene EGFR and lung carcinoma.